Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02003365 · ClinicalTrials.gov registry record · Phase 2
Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee
A Phase 2 study, sponsored by Pacira Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT02003365 is a Phase 2 study that has completed, run by Pacira Pharmaceuticals. The registered enrollment target is 50 participants.
The verdict
NCT02003365, a Phase 2 study, has completed, sponsored by Pacira Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study was to characterize the local duration of exposure of TCA for 2 doses of FX006 relative to 40 mg of TCA IR in patients with OA of the knee.
Interventions
- DRUG TCA IR 40 mg
- DRUG FX006 10 mg
- DRUG FX006 40 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2013-11 |
| Est. Completion | 2014-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02003365
The ClinicalTrials.gov registry entry for NCT02003365 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pacira Pharmaceuticals, which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which TCA IR 40 mg is the first listed.
NCT02003365 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02003365 about?
NCT02003365 is a clinical study titled "Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee". The purpose of this study was to characterize the local duration of exposure of TCA for 2 doses of FX006 relative to 40 mg of TCA IR in patients with OA of the knee.
What is the current status of trial NCT02003365?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2013-11. Estimated completion is 2014-04.
What interventions are being tested in trial NCT02003365?
The interventions under investigation include: TCA IR 40 mg (DRUG), FX006 10 mg (DRUG), FX006 40 mg (DRUG).
Who is sponsoring clinical trial NCT02003365?
This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.